Alzheimer's Association Statement on Lecanemab Phase 3 Full Results
November 30, 2022
November 30, 2022
CHICAGO, Illinois, Nov. 30 (TNSjou) -- The Alzheimer's Association issued the following news release:
The Alzheimer's Association welcomes and is further encouraged by the full Phase 3 data presented by Eisai and Biogen from the CLARITY AD global clinical trial of lecanemab. The data presented today and published in the New England Journal of Medicine confirms this treatment can meaningfully change the course of the disease for people in the earliest stages of Alzheimer� . . .
The Alzheimer's Association welcomes and is further encouraged by the full Phase 3 data presented by Eisai and Biogen from the CLARITY AD global clinical trial of lecanemab. The data presented today and published in the New England Journal of Medicine confirms this treatment can meaningfully change the course of the disease for people in the earliest stages of Alzheimer� . . .